2019 Translational Partners Investment Forum
A medical device startup company that has revolutionized autograft harvesting with our flagship product – the Avitus Bone Harvester.
Developing a new topical formulation for improving wrinkles and treating or preventing dermal disorders.
C-HEART, provides the physician with clinically validated indices of coronary blood flow physiology from a static coronary CT image to determine whether the patient should undergo a catheterization or another intervention is required.
Has developed the first restorative therapy to address pediatric and adult Short Bowel Syndrome (SBS).
Developing diagnostics and therapies based on a proprietary ligand PSMA-1 that binds to PSMA cell membrane receptors overexpressed in prostate cancer and some head, neck and lung cancer subtypes and the neovasculature of most solid tumors.
An early stage cell therapy company that aims to provide a safe and effective mesenchymal cell therapy to address acute and chronic immune disorders.
Commercializing the cardia leaflet enhancer (CARLEN) implant and transfemoral catheter system for repair of functional mitral (FMR) and tricuspid (FTR) valve regurgitation.
Palmm has developed an electronic antiperspirant for excessive sweating of hands and other body parts that lasts a whole week.
Developing Electrast, a voltage-activated ultrasound imaging agent that will allow clinicians to assess and monitor the microperfusion of the hart at the bed-side, in real-time, using traditional ultrasound techniques.
Delivering biologically inspired solutions to restore patient mobility. Our first product is a bioresorbable graft to improve outcomes associated with bone/tendon interface ruptures, e.g., rotator cuff tears.
XaTek ClotChipTM system is an in vitro diagnostic assay delivered in a handheld, point-of-care device with full connectivity that can assess a patient’s bleeding profile in minutes with sensitivity to clinical conditions where no technology can today.
ZEPHYRx uses video games to increase patient compliance to prescribed respiratory therapy to reduce the incidence of hospital-acquired pneumonia and help COPD and asthma patients.